he emerging field of Biosimilars requires some adaptation from the relevant healthcare practitioners, as these complex molecules seem to defy the known facts related to simple chemical entities. Find out why.
Auristatins are a family of complex analogues to the native antineoplastic product dolastatin 10. They are 100 to 1000 times more toxic than Doxorubicin, a conventional cancer chemotherapy medication. https://www.creative-biolabs.com/adc/auristatins.htm
Gel Company provides products with superior performance that are simple, safe and environmentally friendly. Gel Company offers accessories for the following Applied Biosystems products.
Hi All,
Now you can download my Presentation easily. I changed my Privacy setting.. I wish I can make more presentations for the young salesmen, but I am so busy these days and couldn't reply everyone who need my presentation. So here you can download now and present it to your teams etc.
Regards,
Shahzad Chohan
Biosimilars, a pharmacist’s perspectiveBiosimilars
Not many things can profoundly affect and perhaps even alter a profession, let alone the pharmacist’s profession. However, biosimilars might do just that.
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017Fight Colorectal Cancer
Specialty pharmacist Stevan Lalich of CVS Health breaks down the differences between biosimilar, biologic, generic, and brand name drugs – and why it’s important! In this comprehensive webinar, learn about the medicines in your cabinet and the process they endure before reaching you. This is a timely and unique webinar not to be missed
Auristatins are a family of complex analogues to the native antineoplastic product dolastatin 10. They are 100 to 1000 times more toxic than Doxorubicin, a conventional cancer chemotherapy medication. https://www.creative-biolabs.com/adc/auristatins.htm
Gel Company provides products with superior performance that are simple, safe and environmentally friendly. Gel Company offers accessories for the following Applied Biosystems products.
Hi All,
Now you can download my Presentation easily. I changed my Privacy setting.. I wish I can make more presentations for the young salesmen, but I am so busy these days and couldn't reply everyone who need my presentation. So here you can download now and present it to your teams etc.
Regards,
Shahzad Chohan
Biosimilars, a pharmacist’s perspectiveBiosimilars
Not many things can profoundly affect and perhaps even alter a profession, let alone the pharmacist’s profession. However, biosimilars might do just that.
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017Fight Colorectal Cancer
Specialty pharmacist Stevan Lalich of CVS Health breaks down the differences between biosimilar, biologic, generic, and brand name drugs – and why it’s important! In this comprehensive webinar, learn about the medicines in your cabinet and the process they endure before reaching you. This is a timely and unique webinar not to be missed
The present slide focuses on the applications and different uses of biosimilars along with the basic difference in between biosimilars and bioequivalence.
By 2020, it is predicted that the Biosimilar market globally will cross US$20 Billion. With an increasing number of patent expires and more clear regulation processes, Biosimilars have emerged as one of the fastest-growing categories in the bio-pharmaceutical sector. The increasing need for cost-effective treatment is one of the major factors driving this market’s growth in the coming years. Biosimilars cost 10% to 30% lesser than their parent products which is one of the primary factors fueling their adoption.
Pharmacovigilance Risk Management for BiosimilarsCovance
This paper focuses on pharmacovigilance (PV) and risk management for biosimilars, the issues and challenges faced in monitoring their safety and possible solutions.
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.
The first generation of biological drugs, which
have introduced many revolutionary treatments to life threatening and rare illnesses, is currently facing patent expiration. As a result, research-based and generics pharmaceutical companies alike are pursuing the opportunity to develop “generic” substitutes to original biologics, which are also known as biosimilars.
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024Neo4j
Neha Bajwa, Vice President of Product Marketing, Neo4j
Join us as we explore breakthrough innovations enabled by interconnected data and AI. Discover firsthand how organizations use relationships in data to uncover contextual insights and solve our most pressing challenges – from optimizing supply chains, detecting fraud, and improving customer experiences to accelerating drug discoveries.
More Related Content
Similar to Change your mindset – on biosimilars and generics
The present slide focuses on the applications and different uses of biosimilars along with the basic difference in between biosimilars and bioequivalence.
By 2020, it is predicted that the Biosimilar market globally will cross US$20 Billion. With an increasing number of patent expires and more clear regulation processes, Biosimilars have emerged as one of the fastest-growing categories in the bio-pharmaceutical sector. The increasing need for cost-effective treatment is one of the major factors driving this market’s growth in the coming years. Biosimilars cost 10% to 30% lesser than their parent products which is one of the primary factors fueling their adoption.
Pharmacovigilance Risk Management for BiosimilarsCovance
This paper focuses on pharmacovigilance (PV) and risk management for biosimilars, the issues and challenges faced in monitoring their safety and possible solutions.
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.
The first generation of biological drugs, which
have introduced many revolutionary treatments to life threatening and rare illnesses, is currently facing patent expiration. As a result, research-based and generics pharmaceutical companies alike are pursuing the opportunity to develop “generic” substitutes to original biologics, which are also known as biosimilars.
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024Neo4j
Neha Bajwa, Vice President of Product Marketing, Neo4j
Join us as we explore breakthrough innovations enabled by interconnected data and AI. Discover firsthand how organizations use relationships in data to uncover contextual insights and solve our most pressing challenges – from optimizing supply chains, detecting fraud, and improving customer experiences to accelerating drug discoveries.
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...Neo4j
Leonard Jayamohan, Partner & Generative AI Lead, Deloitte
This keynote will reveal how Deloitte leverages Neo4j’s graph power for groundbreaking digital twin solutions, achieving a staggering 100x performance boost. Discover the essential role knowledge graphs play in successful generative AI implementations. Plus, get an exclusive look at an innovative Neo4j + Generative AI solution Deloitte is developing in-house.
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
Communications Mining Series - Zero to Hero - Session 1DianaGray10
This session provides introduction to UiPath Communication Mining, importance and platform overview. You will acquire a good understand of the phases in Communication Mining as we go over the platform with you. Topics covered:
• Communication Mining Overview
• Why is it important?
• How can it help today’s business and the benefits
• Phases in Communication Mining
• Demo on Platform overview
• Q/A
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
In his public lecture, Christian Timmerer provides insights into the fascinating history of video streaming, starting from its humble beginnings before YouTube to the groundbreaking technologies that now dominate platforms like Netflix and ORF ON. Timmerer also presents provocative contributions of his own that have significantly influenced the industry. He concludes by looking at future challenges and invites the audience to join in a discussion.
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfPaige Cruz
Monitoring and observability aren’t traditionally found in software curriculums and many of us cobble this knowledge together from whatever vendor or ecosystem we were first introduced to and whatever is a part of your current company’s observability stack.
While the dev and ops silo continues to crumble….many organizations still relegate monitoring & observability as the purview of ops, infra and SRE teams. This is a mistake - achieving a highly observable system requires collaboration up and down the stack.
I, a former op, would like to extend an invitation to all application developers to join the observability party will share these foundational concepts to build on:
Sudheer Mechineni, Head of Application Frameworks, Standard Chartered Bank
Discover how Standard Chartered Bank harnessed the power of Neo4j to transform complex data access challenges into a dynamic, scalable graph database solution. This keynote will cover their journey from initial adoption to deploying a fully automated, enterprise-grade causal cluster, highlighting key strategies for modelling organisational changes and ensuring robust disaster recovery. Learn how these innovations have not only enhanced Standard Chartered Bank’s data infrastructure but also positioned them as pioneers in the banking sector’s adoption of graph technology.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!SOFTTECHHUB
As the digital landscape continually evolves, operating systems play a critical role in shaping user experiences and productivity. The launch of Nitrux Linux 3.5.0 marks a significant milestone, offering a robust alternative to traditional systems such as Windows 11. This article delves into the essence of Nitrux Linux 3.5.0, exploring its unique features, advantages, and how it stands as a compelling choice for both casual users and tech enthusiasts.
Removing Uninteresting Bytes in Software FuzzingAftab Hussain
Imagine a world where software fuzzing, the process of mutating bytes in test seeds to uncover hidden and erroneous program behaviors, becomes faster and more effective. A lot depends on the initial seeds, which can significantly dictate the trajectory of a fuzzing campaign, particularly in terms of how long it takes to uncover interesting behaviour in your code. We introduce DIAR, a technique designed to speedup fuzzing campaigns by pinpointing and eliminating those uninteresting bytes in the seeds. Picture this: instead of wasting valuable resources on meaningless mutations in large, bloated seeds, DIAR removes the unnecessary bytes, streamlining the entire process.
In this work, we equipped AFL, a popular fuzzer, with DIAR and examined two critical Linux libraries -- Libxml's xmllint, a tool for parsing xml documents, and Binutil's readelf, an essential debugging and security analysis command-line tool used to display detailed information about ELF (Executable and Linkable Format). Our preliminary results show that AFL+DIAR does not only discover new paths more quickly but also achieves higher coverage overall. This work thus showcases how starting with lean and optimized seeds can lead to faster, more comprehensive fuzzing campaigns -- and DIAR helps you find such seeds.
- These are slides of the talk given at IEEE International Conference on Software Testing Verification and Validation Workshop, ICSTW 2022.
Encryption in Microsoft 365 - ExpertsLive Netherlands 2024Albert Hoitingh
In this session I delve into the encryption technology used in Microsoft 365 and Microsoft Purview. Including the concepts of Customer Key and Double Key Encryption.
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
Pushing the limits of ePRTC: 100ns holdover for 100 daysAdtran
At WSTS 2024, Alon Stern explored the topic of parametric holdover and explained how recent research findings can be implemented in real-world PNT networks to achieve 100 nanoseconds of accuracy for up to 100 days.
Pushing the limits of ePRTC: 100ns holdover for 100 days
Change your mindset – on biosimilars and generics
1. Change your mindset – on
Biosimilars and Generics
The emerging field of Biosimilars requires some adaptation
from the relevant healthcare practitioners, as these complex
molecules seem to defy the known facts related to simple
chemical entities.
Graeser Associates International
2. “It is not the strongest of the species that survives, nor the most
intelligent that survives. It is the one that is the most adaptable to
change,” said Charles Darwin, and indeed nowhere else is there a
better example of slow adaptation like the one we are witnessing
these days with the penetration of generic biological drugs, or
biosimilars, into the medical world.
The struggle of the regulatory authorities to define the
requirements for approval, and the lagging adaptation of medical
staffs around the world to recognize and comprehend the fact that
we are now facing a brand new class of drugs, makes biosimilars
very intriguing.
3. • Biological drugs, also referred to as biologics, are proteins
which are designed to either mimic or antagonize endogenous
processes, a fact which makes them highly efficient in treating
many medical conditions. The structure of a protein is by far
more complex than that of a relatively simple chemical
molecule.
• Proteins, being constructed of amino acids, have four levels of
structure complexity which include not only the sequence of
the acids and the length of the chain, but also secondary,
tertiary and quaternary folding structures. Comparing a simple
drug like Aspirin (21 atoms) to an average IgG Antibody
(~25,000 atoms), is like comparing the structure and
mechanism of a bicycle to the complexity of a jet plane. It is
thus understood why, unlike chemical molecules which may be
synthesized in a lab by performing chemical reactions,
biological drugs are produced using live cells.
4. • Because of this ability to produce exact copies of chemical
molecules, in the pharmaceutical world we are accustomed to
seeing generic drugs flooding the market once the patent for an
innovative molecule expires. However, in the biological arena,
producing an identical biological copy when the patent for the
original expires is almost impossible since the manufacturing
conditions have to be identical to yield an exact copy of the
protein (as previously mentioned, it is not enough to have the
correct sequence of amino acids, as the folding structures and
post-translational modifications are also crucial).
• That is why follow-on biologics are referred to as
“Biosimilars”, taking into consideration that although similar,
they are not identical. It is essential to understand that the days
of interchangeability of medications, and simple comparative
studies are probably over, and unlike chemical generics, the
safety and efficacy of each new biosimilar will most likely
need to be determined on an individual level.
5. • In our next blog posts, Graeser Associates International will be
exploring the challenges which await the healthcare
practitioners with regard to biosimilars.
• We will also be providing powerpoint presentations, written
reports, and short audio and video presentations through our
Slideshare channel. We will also be selling more detailed
reports and longer audio and video presentations – please see
our biosimilars product page for a list of products
(www.biosimilar.me).
6. • Adv. Ariel Averbuch, RPh, is an advisor on
IP, healthcare and business strategies at
Graeser Associates International (GAI), an
international health care intellectual property
firm, and acts as Chairman at the
Pharmaceutical Society of Israel (PSI). Adv.
Averbuch has been a pharmacist for over 10
years and is also a lawyer and a patent
attorney (Israel), having extensive experience
in the pharmaceutical field. Follow Ariel
Averbuch on LinkedIn and Twitter:
@ArielAverbuch. Follow our biosimilar
communications on Twitter:
@biosimilarsGAI. Email us at
biosimilars@gai-ip.com.